FDA Submission

Agios’ Sickle Cell Pill Lifts Hemoglobin but Misses Pain-Crisis Goal in Phase 3

The mixed efficacy leaves mitapivat’s expansion prospects uncertain during an FDA review in beta thalassemia that targets a Dec. 7 decision.